Skip to main content
SpringerLink
Log in

Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Ten male, normolipaemic, non-obese subjects were given clofibrate 2g daily, fenofibrate 300 mg daily, bezafibrate 600mg daily and probucol 1g daily for eight days, in a crossover study with a wash-out period of 4–8 weeks between each drug regimen. Clofibrate, fenofibrate and bezafibrate caused a significant decrease in serum triglycerides, total cholesterol and LDL-cholesterol concentrations. Probucol caused a significant increase in serum LDL-cholesterol concentration. Serum HDL-cholesterol concentration was significantly increased by bezafibrate and significantly decreased by probucol. All drugs but probucol led to a significant rise in the activity of the plasma lipoprotein lipase; there was not a significant increase in the activity of plasma hepatic lipase after any drug. The activity of plasma lecithin: cholesterol acyltransferase was significantly increased by fenofibrate and probucol. Analysis of the correlations between serum lipids and plasma lipolytic enzymes suggests that the mechanism of the hypolipidaemic action of clofibrate and bezafibrate might be related to increased catabolism of triglyceride-rich particles; that of fenofibrate and probucol was less clear and might be multifactorial in origin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG (1980) Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 302: 1219–1222

    Google Scholar 

  2. Huy DY, Innerarity TL, Wahley RW (1981) Lipoprotein binding to canine hepatic membranes. J Biol Chem 256: 5646–5655

    Google Scholar 

  3. Glomset JA (1968) The plasma lecithin: Cholesterol acyltransferase reduction. J Lipid Res 9: 155–167

    Google Scholar 

  4. Tall AR, Small DM (1978) Plasma high-density lipoproteins. N Engl J Med 299: 1232–1236

    Google Scholar 

  5. Greten H, Laible V, Zipperle G, Augustin J (1977) Comparison of assay methods for selective measurement of plasma lipase. Atherosclerosis 26: 563–572

    Google Scholar 

  6. Boberg J, Boberg M, Gross R, Grundy S, Augustin J, Brown V (1977) The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia. Atherosclerosis 27: 499–503

    Google Scholar 

  7. Nikkilä EA, Huttunen JK, Ehnholm C (1977) Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 26: 179–186

    Google Scholar 

  8. Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkilä EA (1979) Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301: 1073–1076

    Google Scholar 

  9. Wallentin L (1978) Lecithin: Cholesterol acyl transfer rate and high density lipoproteins in plasma during dietary and clofibrate treatment of hypertriglyceridemic subjects. Atherosclerosis 31: 41–52

    Google Scholar 

  10. Pignard P (1980) Le probucol. Propriétés physico-chimiques et méthodes de dosage. Nouv Presse Med 9: 2973–2975

    Google Scholar 

  11. Lopes-Virella MF, Stone M, Ellis S, Colwell JA (1977) Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 23: 882–884

    Google Scholar 

  12. Friedwald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502

    Google Scholar 

  13. Stokke KT, Norum KR (1971) Determination of lecithin: Cholesterol acyltransfer in human blood plasma. Scand J Clin Lab Invest 27: 21–27

    Google Scholar 

  14. Heller F, Desager JP (1978) Plasma lecithin: Cholesterol acyltransferase: Lack of induction by phenobarbital in humans. Artery 4: 231–238

    Google Scholar 

  15. Nilsson-Ehle P, Ekman R (1977) Rapid, simple and specific assays for lipoprotein lipase and hepatic lipase. Artery 3: 194–209

    Google Scholar 

  16. Harvengt C, Desager JP (1977) Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol 15: 1–4

    Google Scholar 

  17. Desager JP, Harvengt C (1978) Clinical pharmacokinetic study of procetofene a new hypolipidemic drug in volunteers. Int J Clin Pharmacol Biopharm 16: 570–574

    Google Scholar 

  18. Abshagen U, Bablok W, Koch K, Lang PD, Schmidt HAE, Senn M, Stork H (1979) Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 16: 31–38

    Google Scholar 

  19. Meloy D, Caldwell WJ (1978) Analysis and validation of DH-581 in plasma using HPLC-UV. Report NBL 166 of the Dow Chemical Company, USA

  20. Harvengt C, Heller F, Desager JP (1980) Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery 7: 73–82

    Google Scholar 

  21. Olsson AG, Rössner S, Walldius G, Carlson LA, Lang PD (1977) Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 27: 279–287

    Google Scholar 

  22. Heller F, Desager JP, Harvengt C (1981) Plasma lipid concentrations and lecithin: Cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol. Metabolism 30: 67–71

    Google Scholar 

  23. Riesen WF, Keller M, Mordasini R (1980) Probucol in hypercholesterolemia. A double blind study. Atherosclerosis 36: 201–207

    Google Scholar 

  24. Hunninghake DB, Bell C, Olson L (1980) Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia. Atherosclerosis 27: 469–474

    Google Scholar 

  25. Mellies MJ, Gartside PS, Glatfelter L, Vink P, Guy G, Schonfeld G, Glueck JC (1980) Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia. Metabolism 29: 956–964

    Google Scholar 

  26. McCaughan D (1982) Nine years of treatment with probucol. Artery 10: 56–70

    Google Scholar 

  27. Heeg JF, Tachizawa H (1980) Taux plasmatiques du probucol chez l'homme après administration orale unique ou répétée. Nouv Presse Med 9: 2990–2994

    Google Scholar 

  28. Taylor KG, Holdsworth G, Galton DJ (1977) Clofibrate increases lipoprotein-lipase activity in adipose tissue of hypertriglyceridaemic patients. Lancet 2: 1106–1107

    Google Scholar 

  29. Lithell H, Boberg J, Hellsing K, Lundqvist G, Vessby B (1978) Increase of the lipoprotein-lipase activity in human skeletal muscle during clofibrate administration. Eur J Clin Invest 8: 67–74

    Google Scholar 

  30. D'Costa MA, Smigura FC, Kulhay K, Angel A (1977) Effects of clofibrate on lipid synthesis, storage, and plasma intralipid clearance. J Lab Clin Med 90: 823–836

    Google Scholar 

  31. Vessby B, Lithell H, Hellsing K et al. (1980) Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. Atherosclerosis 37: 257–259

    Google Scholar 

  32. Vessby B, Lithell H, Lederman H (1982) Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate. Atherosclerosis 44: 113–118

    Google Scholar 

  33. Klose G, Behrendt J, Vollmar J, Greten H (1980) Effect of bezafibrate on the activity of lipoprotein lipase and hepatic triglyceride hydrolase in healthy volunteers. In: Greten H, Lang PD, Schettler G (eds) Lipoproteins and coronary heart disease — New aspects in the diagnosis and therapy of disorders of Lipid Metabolism. Gerhard Witzstrock, Baden-Baden, FRG, p 182

    Google Scholar 

  34. Miettinen TA, Huttunen JK, Kuusi T, Kumlin T, Mattila S, Naukkarinen V, Strandberg T (1981) Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase. Clin Chim Acta 113: 59–64

    Google Scholar 

  35. Miettinen TA, Huttunen JK, Kuusi T, Kumlin T, Mattila S, Naukkarinen V, Strandberg T (1982) Clinical experience with probucol with special emphasis on mode of action and long-term treatment. Artery 10: 35–43.

    Google Scholar 

  36. Nestel PJ, Billington T (1981) Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 38: 203–209

    Google Scholar 

  37. Simons LA, Balasubramaniam S, Beins DM (1981) Metabolic studies with probucol in hypercholesterolaemia. Atherosclerosis 40: 299–308

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacothérapie, Université Catholique de Louvain, Bruxelles, Belgium

    F. Heller & C. Harvengt

Authors
  1. F. Heller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Harvengt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heller, F., Harvengt, C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 25, 57–63 (1983). https://doi.org/10.1007/BF00544015

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00544015

Key words

Search

Navigation